Premium
P1‐046: BASELINE CHARACTERISTICS FROM CREAD2: A PHASE III TRIAL OF CRENEZUMAB IN EARLY (PRODROMAL‐TO‐MILD) ALZHEIMER'S DISEASE
Author(s) -
Sink Kaycee,
Warren Francis,
Smith Jillian,
Schneider Andres,
Fuji Rei.,
Quartino Angelica,
Mackey Howard,
Rabbia Michael,
Yule Susan,
Fontoura Paulo,
Doody Rachelle,
Ostrowitzki Susanne
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.06.071
Subject(s) - placebo , medicine , clinical endpoint , dementia , amyloid (mycology) , randomization , randomized controlled trial , oncology , disease , pathology , alternative medicine
developed using a similar Methodology to an established ADAScog disease progression model (Ref 1). Parameters describing placebo response were first estimated and fixed based on the published model and using the trial data from the placebo arm. Then Akaike Information Criteria (AIC) were used to select among alternative drug effect models (effects on the underlying progression rate vs an offset with no change in underlying progression rate). The best model was then tested for doseand exposure-dependency in the drug effect.Results: Models describing the drug effect as a detrimental offset occurring early in therapy without a change in underlying progression rate resulted in a large drop in AIC for ADAScog13 (-129), ADAS-cog11 (-105.7), and CDR-SB (-21.9) and a moderate drop in ADCS-ADL (-6.9) indicating a statistically favorable model (<-10.8 corresponds to p<0.001 for a nested comparison with 1df), while inclusion of a drug effect of altered progression rate resulted in little change in AIC. Addition of doseor exposure-dependency on the offset drug effect term resulted in little change in AIC for all 4 endpoints suggesting a lack of significant difference in drug effects across doses and drug exposures investigated. The magnitude of the drug effect offset at the 12 and 40 mg doses was estimated as 1.9 and 2.5 for ADAS-cog13, 1.4 and 1.9 for ADAS-cog11, 0.27 and 0.37 for CDR-SB, and -0.53 and -0.43 for ADCS-ADL, respectively.Conclusions: Overall, these Results indicate that the detrimental verubecestat drug effect in APECS occurred rapidly and did not alter the underlying disease progression rate, but rather acted as an offset. This drug effect was similar in magnitude across the doses and range of drug exposures studied. Ref 1. Clin Pharmacol Ther. 2015 Mar;97(3):210-4.